The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

Comparing capecitabine as the fluoropyrimidine component in combination with oxaliplatin (XELOX) in the second-line setting in metastatic colorectal cancer to an infusional combination of 5 ...

The pivotal trials on first-line FOLFOX and FOLFIRI demonstrated a ... but still eligible for aggressive chemotherapy were included. The IROX results cannot, therefore, be generalized to patients ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...

In SPOTLIGHT, 565 patients with locally advanced gastric/GEJ cancer and CLDN18.2 expression were randomized to receive ...